RCS - Oxford Nanopore Tech - London Calling Technology Update

Oxford Nanopore TechnologiesAnnouncement

22/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250522:nRSV7598Ja&default-theme=true

RNS Number : 7598J  Oxford Nanopore Technologies plc  22 May 2025

Oxford Nanopore Technologies plc

London Calling Technology Update

Annual customer conference highlights how Oxford Nanopore's unique molecular
sensing platform empowers real-time insights, consistent results, and
multiomic discovery

22 May 2025

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the
"Company"), the company delivering a new generation of nanopore-based
molecular sensing technology, presented technology and platform updates at the
Company's flagship annual London Calling customer conference. During the
sold-out event, with more than 4,500 registered online and in-person
participants from more than 120 countries, the Company also provided updates
to its long-term innovation pipeline.

Technology and pipeline updates included:

·      Continued enhancement to product performance, reliability and
competitiveness: The presentation highlighted the development of high
throughput workflows, flow cell improvements and new kit chemistries to drive
higher output on the PromethION Flow Cell.

·      Improved analytics and insights for broad applications: Continued
development of EPI2ME, the Company's informatics platform which provides
analysis tools for a growing menu of end-to-end workflows. Updates included
(i) a new high-performance variant caller to increase consistency and
accelerate workflows, especially in production environments where speed and
reproducibility are key drivers and (ii) continued development of base
modification calling, with more than ten modifications now supported. This
enables improved accuracy of methylation detection, without the need for
complex processes required with legacy sequencing technologies.

·      Improving direct RNA sequencing, to accelerate biopharma
workflows with a single streamlined platform: Recent updates to the cDNA kit
and direct RNA workflows enable longer reads and higher output, delivering
industry-leading performance supporting biopharma applications beyond mRNA
Vaccine Quality Control, including drug discovery, sterility testing, and
exploring tissue-specific RNA modifications.

·      Near term focus on regulated product pipeline to driving adoption
in applied markets: The GridION Q device is expected to complete CE-IVD
submission in the EU for regulated clinical markets by the end of 2025. The
device will be available for specified partners only. The Q-Line product range
is expanding to include PromethION Q, now expected to launch in 2026, to
broaden the opportunity for human sequencing applications.

·      Ambitious and targeted long-term innovation pipeline: including
the ongoing development of a new voltage-controlled ASIC for high throughput
customers.

·      A roadmap to proteomics: Oxford Nanopore is now making
advancements into providing solutions for protein analysis, a key area for
scientific research and discovery in health and substantial potential for
applied uses in clinical and industrial applications. The Company is currently
developing two complementary approaches: one focused on identifying native
proteins in clinical samples, and another designed for scalable protein
barcoding. Both workflows are in development, with future potential to enable
the direct detection and characterisation of full-length proteins.

 

A detailed written summary and a video replay of the technology talk can be
accessed on the Oxford Nanopore website here
(https://nanoporetech.com/news/london-calling-2025-technology-update) .

 

-ENDS-

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:      ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:           media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Jo Blackshaw and Lisa Jarrett-Kerr

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology for
faster, information rich, accessible and affordable molecular analysis. The
first application is DNA/RNA sequencing, and the technology is in development
for the analysis of other types of molecules including proteins. The
technology is used in more than 125 countries to understand and characterise
the biology of humans and diseases such as cancer, plants, animals, bacteria,
viruses, and whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended for
diagnostic purposes. For more, visit: www.nanoporetech.com
(http://www.nanoporetech.com)

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, delays or challenges in manufacturing or
delivering of products to our customers, suspensions of large projects and/or
acceleration of large products or accelerated adoption of pathogen
surveillance or applied uses of our products. These or other uncertainties may
cause our actual future results to be materially different than those
expressed in our forward-looking statements.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKBBQPBKKKPB